Clinical, subclinical characteristics of primary central nervous system lymphoma treated with whole-brain radiotherapy at Vietnam National Cancer Hospital
Main Article Content
Abstract
Primary central nervous system lymphoma (ΡСNЅL) is a subtype of non-Hodgkin lymphoma restricted to the brain, leptomeninges, spinal cord and eyes without systemic involvement. This rare disease has distinct clinical features, treatment strategies, and prognoses compared to other brain tumors. This is a retrospective cross-sectional study on 21 PCNSL patients who underwent whole-brain radiotherapy at Vietnam National Cancer Hospital from June 2019 to September 2024 to investigate the clinical and subclinical characteristics of this disease. The study recorded that the average age of patients at diagnosis was 59.9 years old, and the male-to-female ratio was 2.5:1. The most common clinical symptom was headache (81%). All patients had tumors located in the brain parenchyma, with the most frequent lesion sites being the deep brain regions (ventricles, thalamus, corpus callosum), accounting for 66.7%. 95.2% of all cases had a pathological diagnosis of diffuse large B-cell non-Hodgkin lymphoma. The MRI characteristics of the tumors were predominantly hypointense to isointense on T1-and T2-weighted sequences, with strong and homogeneous contrast enhancement.
Article Details
Keywords
Primary central nervous lymphoma (PCNSL), whole-brain radiotherapy, clinical, subclinical
References
2. Camilleri-Broet S, Martin A, Moreau A, et al. Primary central nervous system lymphomas in 72 immunocompetent patients: pathologic findings and clinical correlations. Groupe Ouest Est d’etude des Leucenies et Autres Maladies du Sang (GOELAMS). Am J Clin Pathol. Nov 1998;110(5):607-12. doi:10.1093/ajcp/110.5.607
3. Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood, The Journal of the American Society of Hematology. 2016;127(20):2375-2390.
4. Houillier C, Soussain C, Ghesquières H, et al. Management and outcome of primary CNS lymphoma in the modern era: an LOC network study. Neurology. 2020;94(10):e1027-e1039.
5. Nelson DF, Martz KL, Bonner H, et al. Non-Hodgkin’s lymphoma of the brain: can high dose, large volume radiation therapy improve survival? Report on a prospective trial by the Radiation Therapy Oncology Group (RTOG): RTOG 8315. Int J Radiat Oncol Biol Phys. 1992;23(1):9-17. doi:10.1016/0360-3016(92)90538-s
6. Đỗ Huyền Nga, Nguyễn Thị Thu Hường, Nguyễn Thanh Tùng. Đặc điểm lâm sàng và cận lâm sàng của u lympho nguyên phát thần kinh trung ương. Tạp chí Y học Việt Nam. 2024;541(1)
7. Phạm Hải Yến, Nguyễn Ngọc Dũng, Nguyễn Thị Mai. Nghiên cứu đặc điểm lâm sàng, xét nghiệm và kết quả điều trị U lympho không Hodgkin tế bào B lớn nguyên phát thần kinh TW tại Viện Huyết học truyền máu TW. Tạp chí Y học Việt Nam. 2022;520.
8. Hyung J, Hong JY, Kim S, et al. Beta-2 microglobulin as a prognostic factor of primary central nervous system lymphoma. Blood research. 2019;54(4):285-288.
9. Kansara R, Shenkier TN, Connors JM, et al. Rituximab with high-dose methotrexate in primary central nervous system lymphoma. American journal of hematology. 2015;90(12):1149-1154.
10. Aki H, Uzunaslan D, Saygin C, et al. Primary central nervous system lymphoma in immunocompetent individuals: A single center experience. International journal of clinical and experimental pathology. 2013;6(6):1068.
11. Bataille B, Delwail V, Menet E, et al. Primary intracerebral malignant lymphoma: report of 248 cases. Journal of neurosurgery. 2000;92(2):261-266.
12. Abrey LE, Batchelor TT, Ferreri AJ, et al. Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma. Journal of clinical oncology. 2005;23(22):5034-5043.
13. Finn WG, Peterson LC, James C, et al. Enhanced detection of malignant lymphoma in cerebrospinal fluid by multiparameter flow cytometry. American journal of clinical pathology. 1998;110(3):341-346.
14. Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004;103(1):275-282.